drug
nexiguran ziclumeran
Phase 3updated 3mo agoby $REGN REGENERON PHARMACEUTICALS, INC.
Phase 3community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying nexiguran ziclumeran
News(2)
- Intellia finds genetic suspect for liver safety signals with ATTR gene therapyIn November 2025, one patient died after receiving Intellia Therapeutics’ investigational gene silencer for transthyretin amyloidosis.biospace · 4d ago
- 5 companies advancing ATTR assets in the wake of Wainua’s failThe Phase 3 failure of AstraZeneca and Ionis Pharmaceuticals’ antisense therapy in transthyretin amyloid cardiomyopathy last month left the space reeling—and readjusting. BioSpace looks at five con…biospace · 8d ago
Data sources
last refreshed 31m ago
Found something off?
comments(0)
5-min edit window · permanent after that